Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis
Shahroz M. Khan
KHSC College of Osteopathic Medicine, Wichita, USA.
Farhana Nazmin
Bronx Care Health System, Bronx, USA.
Rubela Ray
Bankura Sammilani Medical College, Bankura, India.
Rauann Hachem
Saint James School of Medicine, Illinois, USA.
Briannah Wade
American University of Antigua, New York, USA.
Manal A. Bhinder
CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
Muhammad B. Chaudhry
CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
Marya Syed
Fatima Jinnah Medical University, Lahore, Pakistan.
Ayesha Khan
Karachi Medical and Dental College, Karachi, Pakistan.
Eman Fatima
Akhtar Saeed Medical and Dental College, Lahore, Pakistan.
Imdad Ullah
Khyber Medical College, Peshawar, Pakistan.
*Author to whom correspondence should be addressed.
Abstract
Chronic hepatitis C with cirrhosis is treated with direct-acting antibiotics (DAAs). The aim of this study was to investigate the effect of direct-acting antibodies in the treatment of hepatitis C in cirrhosis. It also examines the proportion of drug-related problems, side effects, and mortality. The Cochrane Library and PubMed were thoroughly searched for the required literature. Fifteen articles were extracted for inclusion in this systematic review and meta-analysis. A total of 16 studies were thoroughly screened. The included studies provided a comprehensive picture of the effects of DAA therapy, spanning multiple study designs and sites Our analysis showed that good responses were observed with DAA regimens and that treatment discontinuation was low due to adverse events a stirring that. Few adverse events were reported, but all were mostly uncontrolled to prevent treatment discontinuation or death. In addition, meta-analytic studies on specific outcomes such as encephalopathy, ascites, hepatocellular carcinoma (HCC), adverse events, and death provided quantitative analysis about the safety of DAAs. Research also shows that DAAs have fewer side effects, deaths, and complications than other treatments.
Keywords: Hepatitis C, direct-acting antivirals (DAAs), liver cirrhosis, systematic review, meta-analysis, safety profile, adverse events, treatment efficacy, chronic liver disease, viral eradication